Adalimumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Adalimumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
610
Registered trials
979
Result records
2
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Adalimumab can convert its Monoclonal antibody profile and TNF-α biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Adalimumab (query alias: adalimumab) |
|---|---|
| Modality / target | Monoclonal antibody; TNF-α; TNF-α inhibitors |
| Highest global status | Approved |
| Originator | AbbVie, Inc. |
| Active developers | AbbVie Deutschland GmbH & Co. KG, AbbVie, Inc., AbbVie GK |
The MCP disease footprint includes Non-radiographic axial spondyloarthritis, Pyoderma Gangrenosum, Pustular psoriasis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07510191 | Phase 4 | Recruiting | 312 | Clinical remission rate |
| ChiCTR2600123180 | Phase 4 | Recruiting | 60 | Change in best-corrected visual acuity (BCVA) from baseline in ETDRS letter score at week 24 of treatment |
| NCT07622771 | Phase 2 | Not yet recruiting | 84 | CR rate |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID Lead-In)
Phase 2/3; n=89; evaluation: not stated. Reported fields: -; -; Baseline (Week 0)(Mean) = 0 ng/mL (Standard Deviation, 0)
LONG-TERM RISK OF MALIGNANCIES WITH UPADACITINIB IN COMPARISON TO ADALIMUMAB IN RHEUMATOID ARTHRITIS UP TO 5 YEARS: POST HOC ANALYSIS OF SIX CLINICAL TRIALS
Not Applicable; n=3788; evaluation: Positive. Reported fields: Malignancies = 6.0 Pts ; Malignancies = 12.0 Pts ; Malignancies = 79.0 Pts
TARGET TRIAL EMULATION TO ESTIMATE THE EFFECTIVENESS OF BIOLOGICS USING REAL-WORLD DATA FROM THE UK JUVENILE IDIOPATHIC ARTHRITIS BIOLOGICS REGISTER
Not Applicable; n=297; evaluation: Positive. Reported fields: ACR Pedi 70(amended): OR = 1.76(95.0% CI, 1.04 - 3.01); ACR Pedi 70(amended): OR = 1.76(95.0% CI, 1.04 - 3.01)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Adalimumab addresses Non-radiographic axial spondyloarthritis, Pyoderma Gangrenosum, Pustular psoriasis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2016-06-01 | Eisai and AbbVie to copromote Humira against gastrointestinal disease | Not disclosed | Financial terms not disclosed |
| 2008-01-29 | Abbott and Eisai Finalize License Agreement in Japan for Additional Indications for Adalimumab, The Only Fully Human Monoclonal anti-TNFα Antibody | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “AAV vector for infecting retina, adalimumab, and use thereof”. The milestone feed surfaced a patent-application signal described as “Detection method and detection kit for TNF alpha drug-resistant antibody”. The milestone feed surfaced a patent-application signal described as “Hybridoma cell strain combination and antibody combination for detecting adalimumab and application of hybridoma cell strain combination and antibody combination”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
